Latest News: Christmas Closure 2014
Please note BCTU will be closed from 4pm on Tuesday 23rd December 2014 until 9am on Monday 5th January 2015.
Birmingham Children’s Hospital Pharmacy will be closed Christmas Day, Boxing Day and New Year’s Day. PREDNOS 2 medication will only be sent out on the following days: service as normal up until 12.00pm on Thursday 18th December 2014, then service will resume Monday 29th December 2014 and Tuesday 30th December 2014. Normal service will fully resume Monday 5th January 2015.
The first patient was randomised to the Prednos 2 trial by Royal Mancher Children’s Hospital on the 19th March 2013.
The PREDNOS 2 study medication has been available since 14th February 2013 and the Online Randomisation and Data Entry application was released on 22nd February 2013.
All MHRA, REC and R&D approvals are now in place. REC approval date 4th December 2012 (Ref: 12/NW/0766) and MHRA CTA approval 28th Nov 2012 (Ref: 21761/0281/001-0001). We are also UK CRN portfolio adopted and look forward to working with the MCRN to make PREDNOS 2 a success (Ref: 13410).
The PREDNOS 2 protocol and documentation has been circulated to all collaborators and is available on the PREDNOS 2 website for centres to use. If you have any queries regarding PREDNOS 2 or need any assistance in completing your SSI form please contact the PREDNOS 2 study office: PREDNOS2@trials.bham.ac.uk.
The PREDNOS 2 Study
The PREDNOS 2 study will evaluate short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome. As in PREDNOS 1, the Chief Investigator is Professor Nick Webb, Royal Manchester Children's Hospital, and the trial is co-sponsored by Central Manchester University Hospitals NHS Foundation Trust and University of Birmingham. The trial has been funded by the National Institute for Health Research Health Technology Assessment programme (HTA 11/119/261). PREDNOS 2 will randomise 300 patients over a 2 year recruitment period and all subjects will be followed up for 12 months.
The total study duration is 4 years. The aim of the study is to evaluate the effectiveness of a six day course of daily prednisolone therapy at the time of Upper Respiratory Tract Infection (URTI) in reducing the development of subsequent nephrotic syndrome relapse in children with relapsing SSNS.
Thank you to all of our collaborators
We would like to take this opportunity to thank all of our collaborators for considering the PREDNOS 2 study. We have received an exceptional amount of interest from centres across the United Kingdom and can now confirm over 120 centres will be participating. Thank you for your support and we look forward to working with you on the PREDNOS 2 study.
PREDNOS 2 start date
The PREDNOS 2 grant start date was 1st October 2012 and as the HTA funding was a rapid call we needed to randomise the first patient by the end of March 2013.